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Summary
 
The cytosolic SHP-1 and transmembrane CD45 protein tyrosine phosphatases (PTP) play crit-
ical roles in regulating signal transduction via the B cell antigen receptor (BCR). These PTPs
differ, however, in their effects on BCR function. For example, BCR-mediated mitogenesis is
 
essentially ablated in mice lacking CD45 (CD45
 
2
 
), but is enhanced in SHP-1–deficient moth-
 
eaten (
 
me
 
) and viable motheaten (
 
me
 
v
 
) mice. To determine whether these PTPs act indepen-
dently or coordinately in modulating the physiologic outcome of BCR engagement, we as-
sessed B cell development and signaling in CD45-deficient 
 
me
 
v
 
 (CD45
 
2
 
/SHP-1
 
2
 
) mice. Here
we report that the CD45
 
2
 
/SHP-1
 
2
 
 cells undergo appropriate induction of protein kinase
activity, mitogen-activated protein kinase activation, and proliferative responses after BCR ag-
gregation. However, BCR-elicited increases in the tyrosine phosphorylation of several SHP-
1–associated phosphoproteins, including CD19, were substantially enhanced in CD45
 
2
 
/SHP-1
 
2
 
,
compared to wild-type and CD45
 
2
 
 cells. In addition, we observed that the patterns of cell sur-
face expression of 
 
m
 
, 
 
d
 
, and CD5, which distinguish the PTP-deficient from normal mice, are
largely restored to normal levels in the double mutant animals. These findings indicate a critical
role for the balance of SHP-1 and CD45 activities in determining the outcome of BCR stimu-
lation and suggest that these PTPs act in a coordinate fashion to couple antigen receptor en-
gagement to B cell activation and maturation.
 
T
 
he pivotal role for B cell antigen receptor (BCR)
 
1
 
stimulation in driving B lymphocyte differentiation
and activation is realized through a complex intracellular
signaling network that biochemically translates BCR en-
gagement to nuclear response. Transmission of ligand bind-
ing signals via this biochemical network is dependent upon
reversible protein tyrosine phosphorylation and mediated
by the relative effects of protein tyrosine kinases (PTKs) and
phosphatases (PTPs; 1, 2). As the BCR lacks intrinsic ty-
rosine kinase activity, tyrosine phosphorylation of its Ig 
 
a
 
and 
 
b
 
 chains after ligand engagement is achieved through
recruitment of cytosolic PTKs, the activities of which cre-
ate phosphotyrosine sites for recruitment and activation of
SH2 domain containing PTKs and other secondary signal-
ing molecules (3). PTK-induced phosphorylation thus pro-
vides the framework for the sequential protein activation
and amalgamation that ultimately serves to couple BCR
stimulation to lymphocyte response.
At present, the regulatory roles for PTPs in BCR signal-
ing are not as well defined as those of PTKs. However, two
PTPs that have been identified as key elements in modulat-
ing the outcome of BCR engagement are the CD45 trans-
membrane and SHP-1 cytosolic proteins, enzymes that are
both expressed in hemopoietic cell lineages (4, 5). Analyses
of CD45-deficient mutant cell lines as well as B cells from
mice genetically deficient for CD45 have indicated that
CD45 activity is used to couple BCR stimulation to cell
proliferation (6–8). The involvement of CD45 in B cell dif-
ferentiation has also been revealed by the recent findings
that CD45-deficient mice manifest a reduction in splenic
B cells with phenotypic markings of the mature B cell pool
(8). Together, these data suggest a critical role for CD45 in
promoting the coupling of BCR stimulation to both B cell
mitogenesis and transit from the immature to mature stage
of differentiation. Similarly, multiple lines of evidence in-
dicate that the SH2 domain–containing SHP-1 tyrosine
phosphatase plays a major role in the regulation of BCR
signaling capacity. These data include, for example, the dem-
onstration that loss of function mutations in the SHP-1
 
1
 
Abbreviations used in this paper:
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me
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me
 
v
 
, viable motheaten; PTK, protein tyrosine ki-
nase; PTP, protein tyrosine phosphase.
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gene are responsible for the severe haemopoietic abnormal-
ities found in motheaten (
 
me
 
) and viable motheaten (
 
me
 
v
 
)
mice (9, 10). These animals, which express no (
 
me
 
) or cata-
lytically compromised (
 
me
 
v
 
) SHP-1, manifest high levels of
serum immunoglobulins and autoantibodies. In addition,
they exhibit a profound reduction in conventional B-2
cells, but an overexpansion of CD5
 
1
 
 B-1 cells in the pe-
riphery (11, 12). B cells from 
 
me
 
 and 
 
me
 
v
 
 mice have also
been shown to be hyperresponsive to BCR stimulation,
the mutant cells proliferating in response to normally sub-
mitogenic concentrations of F(ab
 
9
 
)2 anti-Ig antibody, but
responding normally to other mitogenic stimuli such as
LPS (13). Developing B cells from 
 
me
 
v
 
 mice bearing hen
egg lysozyme (HEL) and anti-HEL transgenes have also
been shown to be hyperresponsive to HEL stimulation, the
anti-HEL–bearing SHP-1–deficient cells undergoing dele-
tion when exposed to a level of antigen below that nor-
mally required to induce deletion in this system (14). To-
gether, these data indicate a major role for SHP-1 in
modulating B cell development and in regulating the sig-
naling events linking the BCR to both proliferation and
clonal deletion/negative selection. In contrast to CD45,
however, SHP-1 effects on BCR signaling appear largely
inhibitory, a contention also consistent with recent data
indicating that SHP-1 interacts with and modulates the
signaling functions of both the Fc
 
g
 
RIIB1 and CD22 re-
ceptors, two transmembrane molecules also implicated in
the downregulation of BCR-elicited signaling cascades
(15–18).
Although the available data indicate opposing effects of
CD45 and SHP-1 on the signaling events triggered by BCR
engagement, it is currently unclear whether these PTPs ex-
ert their antagonistic effects by coordinate regulation of a
single signaling pathway or by the modulation of distinct,
parallel signaling cascades involving disparate downstream
signaling effectors. It is also unclear whether the effects of
these individual PTPs on B cell maturation are realized via
the modulation of BCR signaling capacity and, in particu-
lar, through the alteration of BCR thresholds for signal
propagation to the nucleus. To address these issues, we have
examined the ontogeny and signaling properties of the B
lineage population that develops in mice lacking both the
CD45 and SHP-1 tyrosine phosphatases. Analysis of these
mice has revealed their expression of a peripheral B cell
population comprised largely of mature, conventional B-2
cells that proliferate in response to BCR engagement. As
described herein, these data strongly suggest that SHP-1
and CD45 act in concert to modulate the coupling of BCR
stimulation to mitogenesis and maturation.
 
Materials and Methods
 
Cell Preparation and Proliferation Analysis.
 
Single cell suspen-
sions of splenic B cells were obtained from the PTP-deficient
control mice after previously published procedures (8, 13). For
FACS
 
Ò
 
 analysis, the spleen cells were subjected to erythrocyte ly-
sis in ammonium chloride. Cells (1–5 
 
3
 
 10
 
5
 
/sample) were
stained by standard procedures using FITC–anti-IgM (hybridoma
 
33-60), PE–anti-IgD (Southern Biotechnology Assoc., Birming-
ham, AL), and PE–anti-CD5 (PharMingen, San Diego, CA) anti-
bodies and 10
 
4
 
 cells/sample were analyzed on a FACScan
 
Ò
 
 flow
cytometer (Becton Dickinson, San Jose, CA). For proliferation
assays, single cell suspensions of splenic cells were subjected to
erythrocyte lysis in ammonium chloride, T cell lysis by anti-
CD4/CD8/Thyl.2 antibody and complement treatment, and
separation over Percoll gradients as previously described (8, 13).
The purified splenic B cells (
 
.
 
80% sIg
 
1
 
 by FACS
 
Ò
 
) were cul-
tured (5 
 
3
 
 10
 
4
 
 cells/well) for 48 h in culture media alone or in
the presence of 5 
 
m
 
g/ml B76 (rat IgG1 anti–mouse IgM) or 15
 
m
 
g/ml LPS, and proliferation was evaluated after a 6-h pulse with
1 
 
m
 
Ci/well [
 
3
 
H]thymidine (Dupont/New England Nuclear, Bos-
ton, MA). Data are expressed as cpm and values represent means
(
 
6
 
 SEM) of triplicate experiments.
 
Mouse Strain Typing.
 
Genotyping for the 
 
me
 
v
 
 mutation was
carried out by PCR amplifying a 69-bp fragment encompassing
the site of the T
 
®
 
A transversion in the 
 
me
 
v
 
 SHP-1 gene using the
primer pair 5
 
9
 
-CGTGTCATCGTCATGACT-3
 
9
 
 (forward) and
5
 
9
 
-AGGAAGTTGGGGCTTTGCCGT-3
 
9
 
 (back primer that in-
troduces an RsaI site in the vicinity of the mutation) followed by
RsaI digestion of the PCR products. The wild-type SHP-1 allele
is detected as 48- and 21-bp RsaI restriction fragments, whereas
the 
 
me
 
v
 
 allele shows as an intact 69-bp fragment. The genotype
with respect to CD45 was determined by cell surface analysis of
the B220 isoform of CD45 since, as previously described, there is
complete correlation between the presence of B220 and the pres-
ence of the wild-type CD45 gene (19). The CD45
 
2
 
 mice used in
these studies were from the eighth backcross generation to
C57BL/6.
 
Antitopoisomerase Assay.
 
Serial dilutions of sera in PBS/3%
FCS were added to topoisomerase coated wells (Scl-70; Ad-
vanced Biological Products, Brampton, Canada) and incubated
for 1 h at room temperature. Wells were washed, incubated with
goat anti–mouse Ig coupled to horseradish peroxidase (HRP;
Sigma Chemical Co., St. Louis, MO) for 1 h, washed again, in-
cubated with substrate (2,2
 
9
 
-azino-bis; Sigma Chemical Co.), and
absorbance read at 405/630 nm. To quantify the amount of anti-
topoisomerase, serially diluted purified mouse IgG was added to
ELISA plates (Costar Corp., Cambridge, MA) coated with goat
anti–mouse IgG (Sigma Chemical Co.), and the plates were then
washed, blocked with PBS/3% FCS, and developed as described
above. Based on the standard, OD values of 70, 50, and 30 were
estimated to correspond to 
 
z
 
30, 15, and 1 ng/ml, respectively.
 
Histological Analysis.
 
After fixation in formalin and paraffin
embedding, 3-micron sections of renal tissues harvested from nor-
mal and mutant mice were successively incubated at room temper-
ature with rabbit anti–mouse IgM (1.5 h) and biotinylated goat
anti–rabbit (30 min) antibodies (Zymed Labs., Inc., S. San Fran-
cisco, CA), peroxidase-conjugated streptavidin (30 min), and amino-
ethylcarbazole in 0.2 M sodium acetate (15 min; Sigma Chemical
Co.). Sections were then counterstained in hematoxylin and mounted
with Crystal/Mount (Biomeda Corp., Foster City, CA). Original
magnification was at 250. Positive staining is indicated by the red-
brown deposition seen most prominently in the lower left panel
(Fig. 2 
 
C
 
).
 
Immunoprecipitation and Immunoblotting.
 
Before preparation of
cell lysates, purified splenic B cells were resuspended in culture
media at 3 
 
3
 
 10
 
7
 
/ml and left untreated or, alternatively, stimu-
lated for 5 min at 37
 
8
 
C with 5 
 
m
 
g/ml B76 anti-Ig antibody. For
biotinylation, 5–6 
 
3
 
 10
 
7
 
 splenic B cells were resuspended in ice-
cold 1.5 ml PBS and mixed with 15 
 
m
 
l sulfo-NHS-Biotin solu-
tion (Pierce Chem. Co., Rockford, IL). After 30 min of incuba- 
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tion at room temperature, the reaction was quenched by 5 min of
incubation with 500 
 
m
 
g/ml lysine in PBS. Cells were then stimu-
lated as above. For preparation of cell lysates from nonbiotiny-
lated or biotinylated cells, the cells were pelleted by 0.5 min cen-
trifugation and lysed for 15 min in 400 
 
m
 
l cold buffer containing
150 mM NaCl, 50 mM Tris-HCl, pH 8, 2 mM EDTA, 50 mM
NaF, 1 mM PMSF, 1 mM sodium orthovanadate, 0.05% NaN
 
3
 
,
and 1% NP-40. Lysates were then centrifuged at 4
 
8
 
C for 10 min
at 14,000 
 
g
 
, electrophoresed through SDS-polyacrylamide gels,
transferred to nitrocellulose, and incubated at 4
 
8
 
C for at least 1 h
in Tris-buffered saline with Tween solution (150 mM NaCl, 10
mM Tris-HCl, pH 7.4, 0.05% Tween 20) plus 3% gelatin. Filters
were then incubated for 2 h at room temperature with antiphos-
photyrosine antibody (4G10; Upstate Biotechnology Inc., Lake
Placid, NY) in Tris-buffered saline with Tween followed by the
space addition of goat anti–mouse antiserum labeled with peroxi-
dase (Amersham Corp., Arlington Heights, IL) and HRP conju-
gate (Bio Rad Labs., Hercules, CA). Filters derived using protein
lysates from biotinylated cells were also probed with HRP-avidin
(Pierce Chem. Co.). Immune complexes were detected using an
enhanced chemiluminescence system (Amersham Corp.). For im-
munoprecipitations, lysate proteins (1 mg) were precleared by in-
cubation with protein A–Sepharose (Pharmacia, Baie d’Urfe, Que-
bec; 40 
 
m
 
l lysate in 1 ml volume beads) for 1 h at 4
 
8
 
C and for an
additional hour with 40 
 
m
 
l beads and 5 
 
m
 
l rabbit preimmune se-
rum. Lysates were then incubated for 3 h at 4
 
8
 
C with 5 
 
m
 
l anti–
SHP-1 (rabbit polyclonal produced in our lab) or anti-CD19 (rat
monoclonal produced by the ID3 hybridoma) antibodies or rabbit
preimmune serum and 10 
 
m
 
l packed protein A–Sepharose beads
and the immune complexes then collected by centrifugation, washed
in lysis buffer, and resuspended in SDS sample buffer. Samples
were then boiled for 5 min, electrophoresed through 8% SDS-
PAGE, and subjected to immunoblotting analysis as described
above. Stripping and reprobing of the blots were performed ac-
cording to Amersham Corp.’s recommended protocol. Antibody
to mb-1 (rabbit anti–mb-1 cytoplasmic tail) was provided by Dr.
L. Matsuuchi (University of British Columbia, Vancouver, Canada).
 
Assay of Mitogen-activated Protein Kinase Activity.
 
Cell lysates
were prepared from unstimulated and anti-Ig antibody (5 
 
m
 
g/ml
B76)–treated splenic B cells (3 
 
3
 
 10
 
7
 
) from the various PTP-defi-
cient mice and the lysate proteins then immunoprecipitated with
anti-Erk2 antibody (Santa Cruz Labs., Santa Cruz, CA). Equal al-
iquots of the anti-Erk2 immune complexes were then resus-
pended in 25 
 
m
 
l reaction buffer (30 mM Tris-HCl, pH 8.0, 20
mM MgCl
 
2
 
, 2 mM MnCl
 
2
 
 containing 5 
 
m
 
g myelin basic protein
(Upstate Biotechnology Inc.) and 10 
 
m
 
g [
 
g
 
32
 
P]ATP (Dupont/
New England Nuclear). After a 15 min incubation at 30
 
8
 
C, reac-
tions were terminated by addition of 6 
 
m
 
l 5
 
3
 
 loading buffer and the
samples were then boiled, electrophoresed through 15% polyacryl-
amide gels, and the phosphorylated myelin basic protein bands
were visualized by phosphoimaging. Equal aliquots of the re-
maining portions of the anti-Erk2 immunoprecipitates were sepa-
rated by SDS-PAGE, transferred to nitrocellulose, and the filters
were then probed as described above with anti-Erk 2 antibody.
 
Results and Discussion
 
To address the relative contribution of the CD45 and
SHP-1 enzymes to B lymphocyte activation and develop-
ment, mice lacking both SHP-1 and CD45 activities were
derived by breeding the 
 
me
 
v
 
 mutation, which engenders
expression of catalytically compromised SHP-1, into mice
homozygous for a CD45–exon 6 null mutation (9, 19).
Double mutant (CD452/SHP-12) mice derived from these
matings developed the wasting disease normally associated
with the lack of SHP-1, and consequently manifested se-
vere runting and early mortality. However, in contrast to
the splenomegaly characteristically found in the mev ho-
mozygous (mev or CD451/SHP-12) mice (11, 12), splenic
size was markedly reduced in the double mutant animals As
a consequence of these differences, double mutant litter-
mate and age-matched wild-type control mice differed sig-
nificantly with respect to splenic cellularity and composi-
tion. Thus, assessment of peripheral B cell populations in
these animals requires consideration of not only absolute
cell numbers, which depend highly on individual animal
size, and particularly spleen size, but also evaluation of the
relative frequencies of the cell populations being studied.
Accordingly, to examine the effects of combined CD45/
SHP-1 deficiency on B cell development, the presence of
mature splenic B cells was assessed in the double mutant
mice derived from these matings by evaluating the propor-
tion as well as absolute numbers of four splenic cell popula-
tions distinguished by relative levels of cell surface m and d.
As shown by the representative example in Fig. 1, flow
cytometric analysis of splenic cells obtained from double
mutant mice (CD452/SHP-12) revealed the proportion of
dhimlo B cells to be similar to that detected in wild-type
(CD451/SHP-11) spleens (48 versus 45%). This result sug-
gests that progression to the mature and active stage of B
cell differentiation occurs despite the absence of these two
PTP activities. By contrast, the proportion of dhimlo cells in
the splenic B cell compartment of CD452 mice is markedly
reduced relative to that detected in wild-type mice (7 com-
pared to 45%). In absolute terms, the CD452 mice have
threefold fewer dhimlo splenic B cells than do normal mice,
despite having twice as many total splenic B cells. Mev mice
also have fewer dhimlo B cells in absolute terms, but this re-
duction parallels the reduced size of these animals and the
reduced number of B lineage cells present. Fig. 1 also
shows that two populations which emerge in mev spleens
(d2m1 and d1m2 populations) are eliminated in the normal
double mutant mice. A further manifestation of impaired B
cell differentiation in mev mice is the marked over expres-
sion of CD5-expressing B-1 cells. These cells constitute the
majority of splenic B cells in SHP-12 mice (see legend to
Fig. 1), but represent only a minor population in the B cell
compartments of either wild-type or CD452 mice. The
proportion of CD51 splenic B cells is significantly reduced
in double mutant CD452/SHP-12 mice, although their
levels remain higher than normal indicating a failure to
completely restore normal B cell development. It is possi-
ble, for example, that the B cell development in the double
mutant mice is still subjected to trans effects mediated by
abnormal monocytes. Nonetheless, these observations re-
veal the development of significant numbers of conven-
tional B-2 cells in CD452/SHP-12 mice, a population that
fails to develop in CD451 mice deficient for SHP-1. They584 B Cell Signaling Thresholds Mediated by the Balance of Phosphatases
also reveal that CD452/SHP-12 mice do not suffer the
block in progression of B cells from the dhimhi to the dhimlo
stage of differentiation that is typical of CD452 mice. The
number of dhimlo cells that develop is appropriate for the
small spleens of the double mutant mice. Together these
results strongly suggest that these PTPs act in concert to
promote B cell maturation and activation and specifically
the differentiation events yielding B-1 or B-2 cells.
To investigate the physiologic basis for restoration of
B cells displaying a normal phenotype in the CD452/SHP-12
mice, we examined the proliferative response of splenic B
cells stimulated by BCR ligation. As assessed by [3H]thymi-
dine incorporation, anti-Ig induced proliferative responses
of CD452/SHP-12 B cells were lower in magnitude than
those observed in wild-type cells, but were substantially in-
creased relative to the negligible response detected in simi-
larly treated B cells from CD45-deficient mice (Fig. 2 A).
By contrast, LPS-induced proliferation that has previously
been shown to be unaffected by SHP-1 deficiency (13) was
marginally enhanced in the context of CD45 deficiency,
but markedly diminished in CD452/SHP-12 cells. These
findings suggest a complex interaction between CD45 and
SHP-1 in relation to the coupling of LPS stimulation to B cell
proliferation, and also reveal the capacity of the mev muta-
tion to rescue the BCR signaling defect engendered by
CD45 deficiency. Previous data have indicated that BCR-
evoked proliferation is augmented in the absence of SHP-1
(13, 14). Coupled with this observation, the additional data
presented here support the postulate of antigen receptor
signaling thresholds (20). The threshold level required for
transducing a physiologic, BCR-mediated response is pre-
sumably attained in CD452/SHP-12 B cells in which the
inhibitory effects of SHP-1 on the BCR are eliminated,
but not in CD452 B cells in which SHP-1 function is in-
tact. These observations also suggest that the positive selec-
tion of B lymphocytes, as assessed by the progression from
dlomhi to dhimhi to the dhimlo stage of B cell development,
depends upon coordinate effects of SHP-1 and CD45 on
BCR signaling capacity. The reduction of CD51 B-1 cells
in CD452/SHP-12 mice further suggests that BCR-driven
positive selection of not only mature B-2, but also B-1,
cells depends on the interplay between CD45 and SHP-1.
These observations are consistent with other evidence link-
ing B-1 cell development to (auto)antigenic stimulation of
the BCR (21, 22). From this perspective, the expansion of
B-1 cells in SHP-1–deficient mice might be attributable to
the loss of SHP-1 inhibitory effects on BCR activation and
the subsequent indiscriminate triggering of unengaged BCRs.
In CD452/SHP-12 mice, however, the absence of CD45-
positive effects on BCR activation appears to counteract
the heightened “excitability” of mev BCRs so as to mitigate
the preferential selection of B-1 cells. This interpretation of
the data is supported by the findings of reduced splenic B-1
cell numbers in not only CD452 animals, but also Btk-
deficient xid mice (23) as well as mice rendered genetically
deficient for other signaling effectors implicated in the cou-
pling of the BCR to cell response, such as CD19 (24) and
Vav (25).
CD452/SHP-12 mice also exhibited reduced levels of
serum immunoglobulins (data not shown) and autoanti-
bodies, as evaluated by antitopoisomerase antibody titers
(Fig. 2 B). Similarly, renal immune complex deposition was
less evident in CD452/SHP-12 than in SHP-1–deficient
mev mice (Fig. 2 C). However, in contrast to these findings,
overexpansion and tissue accumulation of myelomonocytic
cells were of comparable severity in CD452/SHP-12 and
SHP-12 mice (data not shown) and, as a result, these ani-
mals were indistinguishable in terms of their physical ap-
pearance and survival. These observations concur with pre-
vious data showing that elimination of B-1 cells by addition
of the xid gene has no effect on mev phenotype and mortal-
ity (26). Together, these data suggest that the impact of
SHP-1 and CD45 on the signaling events that promote ac-
tivation and differentiation are different in myeloid and
monocytic cells than in lymphoid cells.
We next addressed the biochemical basis for the dispari-
ties observed in BCR-mediated activation events that dis-
tinguished CD452/SHP-12 B cells from those found in
Figure 1. Representative flow cy-
tometric analyses of splenic B cells
from PTP-deficient mice. Expres-
sion of IgM and IgD was evaluated
on splenic cells from age-matched
4-wk-old mice: CD451/SHP-11
(C57B1/6 wild type); CD452/
SHP-11 (C57B1/6 CD45 exon 62/2;
originally derived by K. Kishihara;
reference 8; eighth backcross gener-
ation), CD451/SHP-12 (C57B1/6
mev/mev); CD452/SHP-12 mice
(derived by mating C57B1/6 CD45
exon 62/2 [eighth backcross gener-
ation] with C57B1/6 mev/1 mice). The percentages of cells within the boxed regions correspond to the following pattern: I, percent d1m2 in the lym-
phoid gate; II, percent dhimlo of III; III, percent d1m1 in the lymphoid gate; IV, percent d2m1 in the lymphoid gate. The lymphoid gate was set by stan-
dard procedures relying on the forward and side scatter properties of the splenic cells. The absolute numbers of various subsets of cells found in the
spleens of the same mice (3 106) for CD451/SHP-11, CD452/SHP-11, CD451/SHP-12, CD452/SHP-12), total splenic cells were 79, 120, 140, and
56, respectively. Lymphoid gate: 68, 95, 95, 41; m1d1: 33, 76, 7.2, 9.1; mlodlo: 15, 5.2, 3.6, 4.4; m1d2, 1.6, 3.4, 8.2, 1.1; m2d1: 0.5, 0.06, 1.6, 0.05;
m1CD51: 5.7 (representing 16% of m1 cells), 4.5 (6%), 11 (71%), 3.6 (37%). Data are representative of four independent experiments carried out as de-
scribed in Materials and Methods.585 Pani et al.
the single PTP-deficient mice. Comparison of biochemical
differences between populations of different developmental
profiles should always be undertaken with caution, since
the observed differences may result from a combination of
direct effects due to the loss of the PTPs in question and
indirect consequences that appear due to the absence of
these PTPs during B cell development. Nonetheless, we
compared these B cell populations by first determining their
profiles of protein tyrosine phosphorylation. As is consis-
tent with previous data linking SHP-1 to the inhibition of
BCR-driven signaling cascades (13, 14) anti-Ig–induced
tyrosine phosphorylation was found to be somewhat in-
creased in the SHP-12 compared to wild-type cells (Fig. 3
A). By contrast, although CD45 has been implicated in
PTK activation after antigen receptor engagement (6, 27),
little difference was detected between stimulated CD452/2
and wild-type, and the CD452/SHP-12 cells with respect
to the pattern or degree of total protein tyrosine phosphor-
ylation. The capacity of SHP-1 deficiency to rescue BCR-
induced proliferative responsiveness in B cells lacking CD45
suggests a role for altered tyrosine phosphorylation of pro-
teins that normally would be dephosphorylated by SHP-1.
We therefore analyzed the tyrosine phosphorylation of pro-
teins coprecipitated with SHP-1 from these B cell popula-
tions after BCR ligation. The results of this analysis revealed
the tyrosine phosphorylation of several SHP-1–associated
phosphoproteins (of z85–90, 115, and 120 kD) to be
strikingly enhanced in both SHP-12 and CD452/SHP-12
cells relative to wild-type B cells. By contrast, the CD452/2
cells exhibited relatively reduced tyrosine phosphorylation
of SHP-1 as well as the various phosphoproteins coprecipi-
tated with this PTP, including a 140-kD species identified
by immunoblotting analysis (data not shown) as CD22, a B
lineage–specific transmembrane glycoprotein implicated in
the negative regulation of BCR signaling (Fig. 3 B) (16–18,
28). In view of preliminary data from our group revealing
the capacity of SHP-1 to associate with CD19, a 115–120-
kD cell-specific transmembrane glycoprotein that is rapidly ty-
rosine phosphorylated after BCR stimulation (29, 30), the
possibility that CD19 is differentially phosphorylated in the
context of CD45 deficiency versus CD45/SHP-1 defi-
ciency was directly investigated. As shown by antiphospho-
tyrosine immunoblotting analysis of CD19 immunoprecip-
itates from the various PTP-deficient B cells (Fig. 3 C),
CD19 phosphorylation was dramatically reduced in the
CD452 cells, but increased both constitutively and after BCR
ligation in the CD452/SHP-12 cells compared to wild-type
B cells. The observation of reduced CD19 phosphorylation
in CD452 cells suggests a role for CD45 activity in promoting
the tyrosine phosphorylation of this membrane glycopro-
tein. This may well be due to the effect of CD45 on the ac-
tivation of the Lyn PTK, an enzyme previously shown to as-
sociate with CD19 (31). Conversely, the enhanced tyrosine
phosphorylation of CD19 observed in SHP-1–deficient B
cells (Fig. 3 B) suggests that SHP-1 exerts an inhibitory in-
fluence over CD19 tyrosine phosphorylation state either by
direct dephosphorylation of this protein or by negative reg-
ulation of a PTK involved in CD19 phosphorylation. This
Figure 2. B cell proliferative responses and autoantibody production in
PTP-deficient mice. (A) Effects of anti-Ig and LPS on proliferation
([3H]thymidine incorporation) of CD452/SHP-12, CD452, and CD451/
SHP-11 (wild-type) B cells (all LPS-treated groups as well as anti-m–treated
groups (CD451/SHP-11) and (CD452/SHP-12) differed significantly
from their counterparts in the No stimulation group based on analysis by a
two-tailed t test (P ,0.05 in all cases). (B) Comparisons of antitopoi-
somerase antibody titers in 4-wk-old CD452/SHP-12, CD452, CD451/
SHP-11 and SHP-12 mice. (C) Immunostaining of renal tissues from
4-wk-old CD451/SHP-11, CD452, CD452/SHP-12, and SHP-12 mice.586 B Cell Signaling Thresholds Mediated by the Balance of Phosphatases
interpretation is supported by the detection of a phospho-
protein that co-migrates with CD19 in SHP-1 immuno-
precipitates, suggesting a capacity for SHP-1 to associate
with CD19 or a CD19-bound protein. Thus, augmented
phosphorylation of CD19 in the CD452/SHP-12 cells likely
reflects the loss of both SHP-1–driven CD19 dephosphoryla-
tion and CD452 dependent, PTK-mediated CD19 phosphor-
ylation. Since CD19 has been shown to serve as a corecep-
tor that positively modulates signal transducing capacity of
the BCR (32), these data suggest that the counterbalance of
CD45 and SHP-1 effects on CD19 recruitment to the
BCR signaling cascade represents one biochemical mecha-
nism whereby these PTPs exert their coordinate regulation
of BCR signaling capacity. This hypothesis, as well as the
identity of the other SHP-1–associated phosphoprotein spe-
cies appearing hyperphosphorylated in the CD452/SHP-12
cells, require further investigation. Nonetheless, the sugges-
tion that CD45 and SHP-1 coordinate effects on BCR
function are realized at the level of CD19 phosphorylation
is consistent with the data indicating a pivotal role for
CD19 in modulating the threshold for coupling BCR
stimulation to not only proliferation, but also to the devel-
opment of B-1 cells (24, 33).
In addition to induction of tyrosine phosphorylation,
anti-Ig elicited activation of the MAP kinase cascade, a more
downstream signaling event that couples BCR-induced
Ras activation to nuclear response, was also examined in
the PTP-deficient cells (34). As shown in Fig. 3 D, analysis
of ERK2-immunoprecipitable kinase activities in these
cells revealed that the induction of MAP kinase activity af-
ter BCR engagement was no different between CD452/
SHP-12 and wild-type cells, but was relatively enhanced in
SHP-12 cells, and essentially abrogated in CD452 cells.
These results indicate a parallel between MAP kinase acti-
vation and the capacities of these PTP-deficient B cells to
proliferate in response to BCR ligation. Thus, the molecular
interactions which allow SHP-1 and CD45 to cooperatively
influence the outcome of BCR engagement appear to oc-
cur at or proximal to activation of the MAP kinase cascade.
In summary, our results indicate that SHP-1 deficiency
rescues antigen-receptor–elicited proliferation in CD45-
deficient mice. The relatively normal splenic B cell pheno-
type observed in the double mutant mice is most likely a
Figure 3. Analysis of SHP-1 phosphoprotein binding and MAP kinase
activation in stimulated B cells from PTP-deficient mice. (A) Comparison
of protein tyrosine phosphorylation in resting and anti-Ig–treated B cells
from wild-type (CD451/SHP-11), CD452CD452/SHP-12, and CD451/
SHP-12 mice. Loading of equivalent amounts of lysate proteins was con-
firmed by reblotting with anti–mb-1 antibody (bottom). (B) Antiphospho-
tyrosine (anti pTyr) immunoblots (top) showing the tyrosine-phosphory-
lated species coprecipitated with SHP-1 from resting and anti-Ig–treated
B cells from wild-type (CD451/SHP-11), CD452, and CD452/SHP-12
mice (left) and from CD451/SHP-12 mice (right). Arrows indicate the
positions of SHP-1 and three associated phosphoproteins that appear dif-
ferentially phosphorylated in the CD452 compared to CD452/SHP-12
and SHP-12 cells. Mobilities of molecular mass standards are shown on
the left. Loading of equivalent amounts of lysate protein was confirmed
by reblotting with anti–SHP-1 antibody (bottom). Data are representative
of three independent experiments on nine mice. (C) Antiphosphotyrosine
immunoblot (top) showing the tyrosine phosphorylation status of CD19
immunoprecipitates derived from biotinylated resting and anti-Ig–treated
wild-type, CD452, and CD452/SHP-12 cells was carried out as de-
scribed in Materials and Methods. The position of CD19 is indicated by
the arrow on the right. Loading of equivalent amounts of CD19 was con-
firmed by reblotting with HRP-avidin (bottom). (D) Representative ex-
ample showing the levels of MAP kinase activities before and 5 min after
BCR ligation in wild-type, CD452, CD452/SHP-12, and CD451/SHP-12
cells (top). Analysis of equivalent amounts of Erk-2 was confirmed by
anti-Erk2 immunoblotting of equivalent aliquots of each Erk-2 immuno-
precipitate (bottom).587 Pani et al.
consequence of the restoration of the selective forces that
promote normal B cell maturation in the spleen. It remains
to be determined whether the effects observed are directly
or indirectly determined by the interactions of the PTPs. It
is possible that altered selection at various levels of B cell
development results in quite distinct populations of splenic
B cells. The signaling defects observed in CD45-deficient
B cells suggest that BCR-mediated activation is normally re-
stricted to conditions that allow the engagement of CD45.
This restriction appears to be required during the final stages
of B cell maturation as transitional cells are recruited into
the mature B cell pool, and may serve to restrain the ampli-
tude of the immune response by setting a threshold for B cell
activation. A key role for SHP-1 in this regulatory circuit is
also apparent as the absence of SHP-1 circumvents the re-
quirement for CD45 in B cell maturation/activation. Thus,
the data reported here, which suggest that the balance of
SHP-1 and CD45 activities substantially influence the out-
come of BCR engagement, identify the biochemical mech-
anisms whereby these PTPs coordinately modulate BCR
activation as being critical to the maintenance of normal B cell
responses and the prevention of autoreactivity.
We thank Caren Furlonger for superb technical assistance with this work, Fengao Xu for scientific contribu-
tions, Lori Mason for her assistance with the immunochemical studies, and Drs. John Cambier, Doug
Fearon, and Tak Mak for their generous contribution of anti-CD22 antibody, anti-CD19 antibody, and
CD452 mice, respectively, for these studies.
This work was supported by grants from the Medical Research Council of Canada and the National Cancer
Institute of Canada. G. Pani is a recipient of a Leukemia Foundation of Canada Fellowship award and a fel-
lowship from the Italian Ministry of Public Education, and K.A. Siminovitch is a Career Scientist of the On-
tario Ministry of Health and an Arthritis Society of Canada Research Scientist.
Address correspondence to Dr. C. Paige, The Wellesley Hospital Research Institute, Wellesley Hospital, 160
Wellesley St. East, Toronto, Ontario M4Y 1J3, Canada. Phone: 416-926-7751; FAX: 416-926-5109;
E-mail: Paige@whri.on.ca
Received for publication 24 January 1997 and in revised form 6 June 1997.
References
1. Cambier, J.C., C.M. Pleiman, and M.R. Clark. 1994. Signal
transduction by the B cell antigen receptor and its corecep-
tors. Annu. Rev. Immunol. 12:457–487.
2. Peaker, C.J.G. 1994. Transmembrane signalling by the B cell
antigen receptor. Curr. Opin. Immunol. 6:359–363.
3. Sefton, B.M., and J.A. Taddie. 1994. Role of tyrosine kinases
in lymphocyte activation. Curr. Opin. Immunol. 6:372–379.
4. Charbonneau, H., and N.K. Tonks. 1988. The leukocyte
common antigen (CD45): a putative receptor-linked protein
tyrosine phosphatase. Proc. Natl. Acad. Sci. USA. 85:7182–
7186.
5. Yi, T., J.L. Cleveland, and J.N. Ihle. 1992. Protein-tyrosine
phosphatase containing SH2 domains. Characterization, pref-
erential expression in hemopoietic cells and localization to
human chromosome 12p12-p13. Mol. Cell. Biol. 12:836–846.
6. Justement, L.B., K.S. Kampbell, N.C. Chien, and J.C. Cam-
bier. 1991. Regulation of B cell antigen receptor signal trans-
duction and phosphorylation by CD45. Science (Wash. DC).
252:1839– 1842.
7. Gruber, M.F., J.M. Bjorndahl, S. Nakamura, and S.M. Fu.
1989. Anti-CD45 inhibition of human B-cell proliferation de-
pends on the nature of activation signals and the state of B cell
activation. A study with anti-IgM and anti-CDw40 antibod-
ies. J. Immunol. 142:4144–4152.
8. Benatar, T., R. Carsetti, C. Furlonger, N. Kamalia, T. Mak,
and C.J. Paige. 1996. A typical B cell development in CD45
deficient mice. J. Exp. Med. 183:329–334.
9. Tsui, H.W., K.A. Siminovitch, L. de Souza, and F.W.L.
Tsui. 1993. Motheaten and viable motheaten mice have mu-
tations in the haematopoietic cell phosphatase gene. Nat.
Genet. 4:124–129.
10. Kozlowski, M., I. Mlinaric-Rascan, G.S. Feng, R. Chen, T.
Pawson, and K.A. Siminovitch. 1993. Expression and cata-
lytic activity of the tyrosine phosphatase PTP1C is severely
impaired in motheaten and viable motheaten mice. J. Exp.
Med. 178:2157–2163.
11. Davidson, W.F., H.C. Morse III, S.O. Sharrow, and T.M.
Chused. 1979. Phenotypic and functional effects of the moth-
eaten gene on murine B and T lymphocytes. J. Immunol. 122:
884–891.
12. Sidman, C.L., L.D. Shultz, R.R. Hardy, K. Hayakawa, and
L.A. Herzenberg. 1986. Production of immunoglobulin iso-
types by Ly-11 B cells in viable motheaten and normal mice.
Science (Wash. DC). 232:1423–1425.
13. Pani, G., M. Kozlowski, J.C. Cambier, G.B. Mills, and K.A.
Siminovitch. 1995. Identification of the tyrosine phosphatase
PTP1C as a B cell antigen receptor–associated protein in-
volved in the regulation of B cell signaling. J. Exp. Med. 181:
2077–2084.
14. Cyster, J.G., and C.C. Goodnow. 1995. Protein tyrosine
phosphatase 1C negatively regulates antigen receptor signalling
in B lymphocytes and determines thresholds for negative se-
lection. Immunity. 2:13–24.
15. D’Ambrosio, D., K.L. Hippen, S.A. Minskoff, I. Mellman,
G. Pani, K.A. Siminovitch, and J.C. Cambier. 1995. Re-
cruitment and activation of PTP1C in negative regulation of588 B Cell Signaling Thresholds Mediated by the Balance of Phosphatases
antigen receptor signalling by Fc gamma RIIB1. Science
(Wash. DC). 268:293–297.
16. Campbell, M.A., and N.R. Klinman. 1995. Phosphoty-
rosine-dependent association between CD22 and protein ty-
rosine phosphatase 1C. Eur. J. Immunol. 25:1573–1579.
17. Doody, G.M., L.B. Justement, C.C. Delibrias, R.J. Mat-
thews, J. Lin, M.L. Thomas, and D.T. Fearon. 1995. A role
in B cell activation for CD22 and the protein tyrosine phos-
phatase SHP. Science (Wash. DC). 269:242–244.
18. Lankester, A.C., G.M.W. van Schijndel, and R.A.W. van
Lier. 1995. Hematopoietic cell phosphatase is recruited to
CD22 following B cell antigen receptor ligation. J. Biol.
Chem. 270:20305–20308.
19. Kishihara, K., J. Penninger, V.A. Wallace, T.M. Kundig, K.
Kawai, A. Wakeham, E. Timms, K. Pfeffer, P.S. Ohashi,
M.L. Thomas, C. Furlonger, C.J. Paige, and T.W. Mak.
1993. Normal B lymphocyte development but impaired T
cell maturation in CD45-exon 6 protein tyrosine phos-
phatase-deficient mice. Cell. 74:143–156.
20. Goodnow, C.C. 1996. Balancing immunity and tolerance:
deleting and tuning lymphocyte repertoires. Proc. Natl. Acad.
Sci. USA. 93:2264–2271.
21. Rabin, E., Y.Z. Cong, and H.H. Wortis. 1992. Loss of CD23
is a consequence of B-cell activation. Implications for the anal-
ysis of B-cell lineages. Ann. NY Acad. Sci. 651:130–142.
22. Hardy, R.R., and K. Hayakawa. 1994. CD5 B cells, a fetal B
cell lineage. Adv. Immunol. 55:297–339.
23. Thomas, J.D., P. Sideras, C.I. Edward Smith, I.Vorechovsky,
V. Chapman, and W.E. Paul. 1993. Colocalization of X-linked
agammaglobulinemia and X-linked immunodeficiency genes.
Science (Wash. DC). 261:355–358.
24. Richert, R.C., K. Rajewsky, and J. Roes. 1995. Impairment
of T cell–dependent B-cell responses and B-1 cell develop-
ment in CD19-deficient mice. Nature (Lond.). 376:352–355.
25. Tarakhovsky, A., M. Turner, S. Schaal, P.J. Mee, L.P.
Duddy, K. Rajewsky, and L.J. Tybulewicz. 1995. Defective
antigen receptor–mediated proliferation of B and T cells in
the absence of Vav. Nature (Lond.). 374:467–477.
26. Scribner, C.L., C.T. Hansen, D.M. Klinman, and A.D.
Steinberg. 1987. The interaction of the xid and me genes. J.
Immunol. 138:3611–3617.
27. Lin, J., V.K. Brown, and L.B. Justement. 1992. Regulation of
basal tyrosine phosphorylation of the B cell antigen receptor
complex by the protein tyrosine phosphatase, CD45. J. Im-
munol. 149:3182–3190.
28. O’Keefe, T.L., G.T. Williams, S.L. Davies, and M.S. Neu-
berger. 1996. Hyperresponsive B cells in CD22-deficient mice.
Science (Wash. DC). 274:798–801.
29. Nadler, L.M., K.C. Anderson, G. Marti, M. Bates, E. Park,
J.F. Daley, and S.F. Schlossman. 1983. B4, a human B lym-
phocyte–associated antigen expressed on normal, mitogen-
activated, and malignant B lymphocytes. J. Immunol. 131:
244–250.
30. Chalupny, N.J., S.B. Kanner, G.L. Schiewen, S. Wee, L.K.
Gilliland, A. Aruffo, and J.A. Ledbetter. 1993. Tyrosine phos-
phorylation of CD19 in pre-B and mature B cells. EMBO
(Eur. Mol. Biol. Organ.) J. 12:2691–2696.
31. Uckun, F.M., A.L. Burkhardt, L. Jarvis, X. Jun, B. Stealey, I.
Dibirdik, D.E. Myers, L. Tuel-Ahlgren, and J.B. Bolen.
1993. Signal transduction through the CD19 receptor during
discrete developmental stages of human B-cell ontogeny. J.
Biol. Chem. 268:21172– 21184.
32. Carter, R.H., and D.T. Fearon. 1992. CD19: lowering the
threshold for antigen receptor stimulation of B lymphocytes.
Science (Wash. DC). 256:105–107.
33. Krop, I., A.R. de Fougerolles, R.R. Hardy, M. Allison, M.S.
Schlissel, and D.T. Fearon. 1996. Self-renewal of B-1 lym-
phocytes is dependent on CD19. Eur. J. Immunol. 26:238-242.
34. Seger, R., and E. Krebs. 1995. The MAPK signalling cascade.
FASEB J. 9:726–735.